[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421608":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":38,"centralContacts":42,"locations":50,"responsibleParty":91,"collaborators":93,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":11,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":11,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"placebo","PLACEBO_COMPARATOR",null,[13],"Drug: Placebo",{"label":15,"type":16,"description":11,"interventionNames":17},"clopidogrel","ACTIVE_COMPARATOR",[18],"Drug: Clopidogrel",{"label":20,"type":16,"description":11,"interventionNames":21},"aspirin",[22],"Drug: aspirin",[24,29,32],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Placebo","patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment",[9],{"type":25,"name":20,"description":30,"armGroupLabels":31,"otherNames":11},"patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment",[20],{"type":25,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Clopidogrel","patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment",[15],[37],"plavix",[39],{"name":40,"affiliation":5,"role":41},"Sharon Chih","PRINCIPAL_INVESTIGATOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":11,"email":46},"CONTACT","613-696-7000","schih@ottawaheart.ca",{"name":48,"role":44,"phone":11,"phoneExt":11,"email":49},"Heather Ross","heather.ross@uhn.ca",[51,68,80],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"St.Pauls Hospital","RECRUITING","Vancouver","British Columbia","V6Z 1Y6","Canada","CA",{"type":60,"coordinates":61},"Point",[62,63],-123.11934,49.24966,{"lat":63,"lon":62},[66],{"name":67,"role":44,"phone":11,"phoneExt":11,"email":11},"Mustafa Toma",{"facility":69,"status":53,"city":70,"state":71,"zip":72,"country":57,"countryCode":58,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"University of Ottawa Heart Institute","Ottawa","Ontario","K1Y 4W7",{"type":60,"coordinates":74},[75,76],-75.69812,45.41117,{"lat":76,"lon":75},[79],{"name":40,"role":44,"phone":11,"phoneExt":11,"email":11},{"facility":81,"status":53,"city":82,"state":71,"zip":83,"country":57,"countryCode":58,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Toronto General Hospital UHN","Toronto","M5G 2C4",{"type":60,"coordinates":85},[86,87],-79.39864,43.70643,{"lat":87,"lon":86},[90],{"name":48,"role":44,"phone":11,"phoneExt":11,"email":11},{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[94],{"name":95,"class":96},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100421608","phase-3-aerial-trial-antiplatelet-therapy-in-heart-transplantation-100421608",false,"NCT04770012","AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial","Inclusion Criteria:\n\n1. Heart transplant\n2. Age ≥18 years\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Allergy or known intolerance to aspirin\n2. Allergy or known intolerance to clopidogrel\n3. Intracranial hemorrhage ≤14 days\n4. Bleeding disorder\n5. Platelet count \\\u003C50 x 109\u002FL\n6. History of aspirin related gastrointestinal bleeding or ulcers\n7. Non-cardiac indication for antiplatelet therapy\n8. Anticoagulation \\>3 months\n9. Allergy to iodinated contrast\n10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2 for non-dialysis patients\n11. Unable to undergo coronary angiography due to unsuitable vascular access\n12. Combined solid organ transplantation.","ALL","18 Years",{"count":107,"type":108},135,"ESTIMATED","INTERVENTIONAL",[111],"PHASE3","Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.",[114,115],"Cardiac Allograft Vasculopathy","Heart Transplant","2026-04-29",{"date":118,"type":119},"2026-05-06","ACTUAL",{"date":121,"type":119},"2021-06-28",{"date":123,"type":108},"2029-03",{"name":5,"class":6},3]